New York State Common Retirement Fund Has $67.79 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

New York State Common Retirement Fund lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 120,569 shares of the biopharmaceutical company’s stock after selling 7,500 shares during the quarter. New York State Common Retirement Fund’s holdings in Regeneron Pharmaceuticals were worth $67,792,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. State Street Corp boosted its stake in Regeneron Pharmaceuticals by 0.9% in the second quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after buying an additional 42,343 shares in the last quarter. Dodge & Cox boosted its stake in shares of Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after purchasing an additional 1,502,198 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.6% during the 2nd quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock valued at $1,214,585,000 after purchasing an additional 36,821 shares during the last quarter. Loomis Sayles & Co. L P increased its position in Regeneron Pharmaceuticals by 18.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after purchasing an additional 305,089 shares in the last quarter. Finally, Norges Bank bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $628,151,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on REGN shares. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Citigroup upped their target price on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price target for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Royal Bank Of Canada boosted their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Finally, Hsbc Global Res upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $784.77.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Trading Down 0.2%

REGN opened at $749.44 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The firm has a market capitalization of $78.77 billion, a PE ratio of 17.95, a P/E/G ratio of 1.96 and a beta of 0.39. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. The company’s 50-day moving average is $758.68 and its 200 day moving average is $648.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the previous year, the firm earned $12.46 EPS. The business’s revenue for the quarter was up .9% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.